地特胰岛素治疗2型糖尿病临床分析

目的总结地特胰岛素治疗2型糖尿病的临床疗效和安全性。方法收集90例2型糖尿病患者,在指导控制饮食的基础上,单用地特胰岛素组35例;地特胰岛素＋瑞格列奈组28例;地特胰岛素＋门冬胰岛素组27例。比较三组疗效。结果 90例患者经地特胰岛素治疗后,其中达标者75例（83.3%）,低血糖发生者5例（5.56%）;三组空腹血糖（FBG）、餐后2 h血糖（2 h PBG）、糖化血红蛋白（Hb A1c）同治疗前相比均有明显下降（P〈0.01）,但三组间差异无统计学意义（P〉0.05）。结论地特胰岛素治疗2型糖尿病无论单独应用,还是联合口服药瑞格列奈或门冬胰岛素,都能有效地控制血糖,而且低血糖的发生率低,值得临床应用。

Clinical analysis of insulin detemir in the treatment of type 2 diabetes mellitus

Objective To summarize the clinical effect and safety of insulin detemir in the treatment of type 2 diabetes mellitus. Methods A total of 90 type 2 diabetes mellitus patients were enrolled. On the basis of diet control and guidance, the single insulin detemir group contained 35 cases, the insulin detemir＋repaglinide group contained 28 cases, and the insulin detemir＋insulin aspart group contained 27 cases. The curative effects of the three groups were compared. Results Among the 90 cases in insulin detemir treatment, there were 75 cases reached standard（83.3%） and 5 cases with hypoglycemia（5.56%）. The levels of fasting blood glucose（FBG）, 2 hours postprandial blood glucose（2 h PBG）, and glycosylated hemoglobin（Hb A1c） were all obviously decreased, compared with those before the treatment（P〈0.01）, while there was no statistically significant difference in the three groups（P〉0.05）. Conclusion In the treatment of type 2 diabetes mellitus, the single application of insulin detemir and combined application with repaglinide or insulin aspart all can effectively control the blood glucose level with a low incidence of hypoglycemia. These treatments are worth clinical application.